| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
刘爱华，张 明. 培美曲塞联合卡铂治疗非小细胞肺癌疗效及安全性的Meta分析[J]. 沈阳药科大学学报，2017(8): 694-700.
|
| 3 |
张伟萍，应海峰，尤匡掌，等. 培美曲塞注射剂联合卡铂注射液治疗表皮生长因子受体-酪氨酸激酶抑制药耐药后晚期肺腺癌患者的临床研究[J]. 中国临床药理学杂志，2018, 34(19): 24-27.
|
| 4 |
Shang B, Jia Y, Chen G, et al. Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells[J]. Respir Res, 2017, 18(1): 56.
|
| 5 |
Kaneda T, Yoshioka H, Tamiya M, et al. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer[J]. Bmc Cancer, 2018, 18(1): 6-7.
|
| 6 |
李子海，贾 慧，宋平平，等. 非小细胞肺癌患者外周血CD44V6 mRNA表达与微转移的相关性研究[J]. 癌症进展，2017, 15(1): 22-25.
|
| 7 |
倪 然，黄永杰. 血清CA125、Cyfra21-1、SCCAg、NSE水平监测在非小细胞肺癌晚期患者靶向治疗疗效评估中的应用价值[J]. 中国卫生工程学，2018, 17(003): 410-412.
|
| 8 |
白云鹏，许 顺. 培美曲塞联合铂类一线药物治疗晚期非鳞型非小细胞肺癌的疗效[J]. 中国医科大学学报，2019, 48(05): 91-93.
|
| 9 |
吴晓文，黄银梅. 培美曲塞联合顺铂治疗非鳞非小细胞肺癌临床观察[J]. 中国处方药，2019, 17(6): 9-11.
|
| 10 |
Paul G, Tim Van den W. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability[J]. PLoS One, 2019, 14(4): 215135.
|
| 11 |
袁 征，李 珍，孙彦珍，等. 培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效研究[J]. 中国临床药理学杂志，2018, 34(7): 790-792.
|
| 12 |
任 洁，芦 兰，程春来，等. 培美曲塞在老年晚期非小细胞肺癌姑息性化疗中的作用[J]. 中国老年学杂志，2017, 37(9): 2195-2196.
|
| 13 |
李 梅，耿一超，杨文刚，等. 培美曲塞+顺铂或多西他赛+顺铂同期胸部IMRT治疗Ⅳ期肺腺癌的疗效和安全性[J]. 中华放射肿瘤学杂志，2018, 27(6): 564-569.
|
| 14 |
俞婷婷，卢 喜，单 莉. 培美曲塞与依托泊苷联合顺铂同步胸部放疗治疗局部晚期肺腺癌的疗效和药物经济学比较研究[J]. 中国全科医学，2018, 21(23): 106-110.
|
| 15 |
赵 永，孙振宇，顾敏威. 吉西他滨与顺铂化疗对非小细胞肺癌行全胸腔镜肺癌根治术后生存质量的影响[J]. 中国地方病防治杂志，2018, 33(1): 115-115.
|
| 16 |
陈 红，周晓红，陆国权，等. 培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究[J]. 中国临床药理学杂志，2017, 33(12): 1079-1081.
|
| 17 |
Kouji I, Hiroaki I, Hiroshi Y, et al. Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function[J]. In Vivo, 2019, 33(1): 167-172.
|
| 18 |
Münch S, Pigorsch SU, Michal D, et al. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus[J]. Radiat Oncol, 2018, 13(1): 139.
|
| 19 |
Shuayb M, Shahi MSJR, Hossen MM. 119P Cisplatin/etoposide or paclitaxel/carboplatin with concurrent radiation therapy in stage ⅢB non-small cell lung cancer: A one-year phase Ⅱ trial at a low resource setting [J]. J Thorac Oncol, 2018, 13(4): 66-67.
|
| 20 |
Fennell D, Danson S, Forster M, et al. MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma[J]. J Thorac Oncol, 2018, 13(10)：397-398.
|
| 21 |
Soetandyo N, Hanafi AR, Agustini S, et al. Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma [J]. Med J Indonesia, 2020, 29(1)：26-31.
|
| 22 |
Wu FY, Zhang SJ, Xiong AW, et al. A phase Ⅱ clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2018, 19(6)：831-842.
|
| 23 |
Khosravi A, Salimi B, Esfahani-Monfared Z, et al. A Phase Ⅳ Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit[J]. Asian Pac J Cancer Prev, 2018, 19(10): 2973-2978.
|
| 24 |
El-Osta HE, Mott FE, Burt BM, et al. Predictors of benefits from frontline chemoimmunotherapy in stage Ⅳ non-small-cell lung cancer: a meta-analysis[J]. OncoImmunology, 2019, 8(12): e1665974.
|
| 25 |
Tanino R, Tsubata Y, Harashima N, et al. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer[J]. Oncotarget, 2018, 9(24): 16807.
|
| 26 |
Cortellini A, Gambale E, Cannita K, et al. Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice[J]. Thorac Cancer, 2018, 9(2): 241-252.
|
| 27 |
Mishra A, Singh N, Sahu DK, et al. 33P Expression of biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of non-small cell lung carcinoma patients detected by real-time PCR[J]. J Thorac Oncol, 2018, 13(4): 18-19.
|
| 28 |
Alessio C, Elisabetta G, Katia C, et al. Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice[J]. Thorac Cancer, 2018, 9(2): 241-252.
|